Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement.

Contois JH, Warnick GR, Sniderman AD.

J Clin Lipidol. 2011 Jul-Aug;5(4):264-72. doi: 10.1016/j.jacl.2011.05.004. Epub 2011 May 27. Review.

PMID:
21784371
2.

Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?

Sniderman A, McQueen M, Contois J, Williams K, Furberg CD.

J Clin Lipidol. 2010 May-Jun;4(3):152-5. doi: 10.1016/j.jacl.2010.03.005. Epub 2010 Mar 18. Review.

PMID:
21122647
3.

Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B.

Stein EA, Sniderman A, Laskarzewski P.

Am J Cardiol. 2005 Nov 7;96(9A):36K-43K; discussion 34K-35K. Epub 2005 Sep 19. Review.

PMID:
16291013
4.

Non-high-density lipoprotein cholesterol: why lower is better.

Garg R, Vasamreddy CR, Blumenthal RS.

Prev Cardiol. 2005 Summer;8(3):173-7. Review.

5.

Role of lipid and lipoprotein profiles in risk assessment and therapy.

Ballantyne CM, Hoogeveen RC.

Am Heart J. 2003 Aug;146(2):227-33. Review.

PMID:
12891189
6.

Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.

Miller M, Ginsberg HN, Schaefer EJ.

Am J Cardiol. 2008 Apr 1;101(7):1003-8. doi: 10.1016/j.amjcard.2007.11.046. Review.

PMID:
18359322
7.

Apolipoproteins as markers and managers of coronary risk.

Chan DC, Watts GF.

QJM. 2006 May;99(5):277-87. Epub 2006 Feb 27. Review. Erratum in: QJM. 2006 Nov;99(11):807.

PMID:
16504986
8.

Reliability of lipid, lipoprotein, and apolipoprotein measurements.

Naito HK.

Clin Chem. 1988;34(8B):B84-94. Review.

PMID:
3042204
9.

Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB.

Sniderman AD, Lamarche B, Contois JH, de Graaf J.

Curr Opin Lipidol. 2014 Dec;25(6):461-7. doi: 10.1097/MOL.0000000000000127. Review.

PMID:
25340478
10.

Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing.

Langlois MR.

Clin Chem Lab Med. 2012 Apr 10;50(7):1169-81. doi: 10.1515/cclm-2011-0636. Review.

PMID:
22850050
11.

[Clinical significance of non-high-density lipoprotein cholesterol and its application in pediatrics].

Chen LH, Shi XF, Liang L.

Zhonghua Er Ke Za Zhi. 2013 Jun;51(6):436-8. Review. Chinese. No abstract available.

PMID:
24120061
12.

Targeting residual risk: the rationale for the use of non-HDL cholesterol.

Alla VM, Kaushik M, Mooss A.

South Med J. 2010 May;103(5):434-7; quiz 438-9. doi: 10.1097/SMJ.0b013e3181d7e3a8. Review.

PMID:
20375942
13.

Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges.

Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR.

Circulation. 2013 Sep 10;128(11):1256-67. doi: 10.1161/CIRCULATIONAHA.113.000962. Review. No abstract available.

14.

[From the Point of View of the Production of Reference Material].

Kuwa K.

Rinsho Byori. 2014 Sep;62(9):895-907. Review. Japanese.

PMID:
27526536
15.

Measurement of cholesterol and other lipoprotein constituents in the clinical laboratory.

Warnick GR.

Clin Chem Lab Med. 2000 Apr;38(4):287-300. Review.

PMID:
10928647
16.

[From the Point of View of Health Evaluation and Promotion (Ningen Dock) Facilities].

Yamashita T, Funatsu K, Kondo S, Yokoyama M, Mizuno K, Nakamura H.

Rinsho Byori. 2014 Sep;62(9):892-4. Review. Japanese.

PMID:
27526535

Supplemental Content

Support Center